The technology under development utilises a novel combination of OCT imaging and elastography to provide a rapid evaluation of tissue microarchitecture at a scale and resolution comparable to histology. The Company’s initial focus is on the development of an imaging probe that will enable breast cancer surgeons to identify residual cancer following the excision of the tumour, providing a solution to address the high re-excision rates for breast cancer patients.
